AzTrials
AzTrials

Glaucoma EyeNCT05895617

Assessment of the Occuity PM1 Pachymeter

An observational study of Glaucoma Eye, run by Occuity Limited at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To determine whether the Occuity PM1 device is non-inferior in measuring central corneal thickness when compared to ultrasound pachymetry, the Lenstar and the Pentacam. The Investigation aims to assess long-term safety of the Occuity PM1 device when used under the conditions and for the purposes intended, to ensure it… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Glaucoma Eye
How many people
100 participants
Where
1 siteUnited Kingdom
Study dates
15 Jan 2023to 19 Apr 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: United Kingdom

Who may be able to join

  • The participant must meet ALL the following criteria to be considered eligible for the study:
  • Male or Female, aged 18 years or above.
  • Participant is willing and able to give informed consent for participation in the study.
  • Able and willing to comply with all study requirements.

Who cannot join

  • The participant may not enter the study if ANY of the following apply:
  • Any ocular surgery within 6 months
  • Known active corneal abnormalities (e.g. Keratoconus, epithelial defects)
  • Previous corrective refractive surgery (e.g. LASIK, PRK)
  • Current ocular inflammatory or infectious disease (e.g. Uveitis, keratitis, corneal ulcers)
  • Contact lens use within the last week
  • Any contraindications to use of topical anaesthetic eye drops
  • Any other pathology which the clinician or investigator believe may affect the accuracy of the CCT measurement

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Occuity Limited

    Reading, Berkshire, RG1 3BE

Other trials in United Kingdom

About this study

Official title: Is the Occuity Pachymeter Non Inferior in it's Measurement of Central Corneal Thickness Compared to the Ultrasound Pachymeter, Lenstar and Pentacam.

To determine whether the Occuity PM1 device is non-inferior in measuring central corneal thickness when compared to ultrasound pachymetry, the Lenstar and the Pentacam.

The Investigation aims to assess long-term safety of the Occuity PM1 device when used under the conditions and for the purposes intended, to ensure it will not compromise the clinical condition or the safety of patients, or the safety and health of users or, where applicable, other persons.

Read more

The central corneal thickness measurements taken by the three devices: Occuity PM1, the ultrasound pachymeter and Lenstar. Demonstrating that the Occuity PM1 Pachymeter is not inferior to the LenStar in terms of equivalency to a 95% confidence level using the Bland Altmen equation/approach based on +/-20micron equivalency.

The investigators would like to measure the thickness of the cornea, which is the clear window at the front of the eye. A corneal thickness measurement is important for several reasons. The measurement can tell an eye care professional if the cornea is swollen, which may mean the particiapnt have an increase in fluid within the cornea. Also, assessing corneal thickness can help in the diagnosis of glaucoma and the measurement is important if the participant is going to have eye surgery.

The instruments that are currently in use are usually very large and quite expensive and therefore not ideal for use as part of routine eye care. Some instruments require contact with the surface of the eye, which may be uncomfortable.

Occuity Ltd. is a medical device company based in Reading, which has been investigating this. They have developed a new instrument (called the 'PM1 Pachymeter') for measuring the thickness of the cornea. The instrument shines a harmless low power beam into the eye and then measures the light reflected back from the eye in order to check the thickness of the cornea. The low power beam is not a visible light and so the participant will not be able to see it. s study will assess how closely the eye measurements taken from the new PM1 Pachymeter matches eye measurements taken from two other devices that are currently on the market. The goal is to provide a non-contact, hand-held meter that is fast and easy to use without the need to contact the eye.

Read the detailed description

The cornea is a thin, transparent structure at the front of the eye; its surface, as well as the overlying tear film, is responsible for the majority of the eye's refractive power.

Accurate and precise measurement of corneal thickness is important in the diagnosis and management of many ocular diseases. In particular, the central corneal thickness (CCT) measurement is a key parameter to consider when planning for procedures such as refractive surgery, and in the diagnosis of glaucoma.

Refractive error is the leading cause of reversible visual impairment worldwide; it is therefore unsurprising corrective refractive surgery is one of the most widely performed procedures globally. In the United Kingdom, the most frequently performed refractive surgery are laser assisted surgical procedures, such as laser assisted in situ keratomileusis (LASIK), Laser epithelial keratomileusis (LASEK), and Photorefractive Keratectomy (PRK). All of these techniques involve ablating the cornea with a laser to achieve a specific shape. Having an accurate measurement of corneal thickness is therefore of utmost importance in the planning stages, as excessive ablation of the cornea can lead to corneal ectasia, a significant complication of refractive surgery .

Glaucoma is a progressive disease which causes irreversible vision loss, and with ever aging populations, it is now one of the leading causes of irreversible blindness worldwide. Although it is considered to be multifactorial in aetiology, with both genetic and acquired factors contributing to its development and progressions, it is still widely accepted that the intraocular pressure (IOP) is the only modifiable factor in its management to prevent or slow further visual loss. (5).

IOP measurement is typically done in hospital clinics using a Goldmann applanation tonometer. The pressure reading is affected by the corneal thickness - a thick cornea will give a falsely elevated IOP reading, which may result in a patient with healthy eyes being commenced on unnecessary treatment, while conversely a thin cornea may give a falsely low pressure reading, which can result in patients with glaucoma not being started on sight-saving treatment. It has been estimated that a 10% increase in CCT can result in an apparent IOP increase of 3.4mmHg (2).

Ultrasound Pachymeter The ultrasound pachymeter (UP) is currently the gold standard method , as well as the most widely used to measure CCT. In comparative device studies, the ultrasound pachymeter has been shown to provide the most repeatable measurements . In addition, it is a small and portable handheld device, which makes it very convenient and timesaving to use during clinic appointments.

However, there are several negative aspects to the UP. First, it is necessary for the device to make direct contact with the cornea, which introduces the risk of corneal abrasions and subsequent infection. Second, anaesthetic eye drops need to be used for the patients to tolerate the corneal touch, and studies have shown that after instillation of anaesthetic eye drops, the CCT measurement is increased compared to before the use of anaesthetic, which can lead to a systematic over-reading of IOP. Third, the UP can be difficult to use, as it is necessary for the probe to contact the cornea perpendicularly, and exactly at the centre of the cornea to achieve the most accurate reading, which is difficult to achieve even with good staff training and experience. Lastly, despite the use of anaesthetic, measurement using this device is uncomfortable, and sometimes poorly tolerated due to the corneal touch, especially by the paediatric population.

While there are optical devices available on the market which can measure CCT without the instillation of anaesthetic or corneal touch, they tend to be bulky machines which are not portable and require specialist training to use. This makes their use in busy hospital clinics and community optometry practices less feasible.

There is a clear need to develop a device which can measure CCT accurately without necessitating corneal touch and use of topical anaesthetic, as well as being easily portable. There is no such device available on the market currently, and in our search in the clinical trial databases and Occuity did not identify any active trials investigating similar devices.

Occuity PM1 Pachymeter The Occuity device is a new handheld, non-contact, optical pachymeter, which utilise a low power, eye safe near infrared (1310nm) beam to measure the corneal thickness.

The device has an intuitive touchscreen display interface, and a series of 9 LEDs which provides the illumination needed to align the device in front of the eye. Once alignment is achieved, the measurement can take place by pressing the start button on the touchscreen display. During preliminary testing at the parent company, it has been shown the alignment and measurement process takes less than 10 seconds in total, after which a reading will be shown on the digital display of the device. The device is reported to have high reliability (variation of approximately 10um with repeat readings of the same eye), and comparable results to the Lenstar LS900 Biometer during initial testing.

The LED light system consist of a partial ring of 9 white LEDs at a radius of 8.75mm and spaced at 30° intervals. The total power is 2.4 mWm-2 which is will within the 10 mWm-2 blue light hazard eye safety limit. The maximum power of the infrared beam is 50µW, which given the expected exposure time of less than 10 seconds, is considered Class 1 eye safe according to BS EN 60825.

Lenstar LS 900 (Haag-Streit AG, Koeniz, Switzerland) The Lenstar is an optical device which utilises an 820mm super-luminescent diode and allows for high resolution measurements of the structures in the eye, including CCT. Its use is well established in the hospital clinic setting, and measurements do not require the use of anaesthetic drops or corneal touch. A drawback of this device is that it is large and heavy, and therefore not portable or as fast to use, unlike the ultrasound pachymeter or the Occuity PM1 device.

Pentacam (Oculus Optikgerate GmbH (Germany) Very similar to the Lenstar, the Pentacam is an optical device which also utilises an 820mm super-luminescent diode and allows for high resolution measurements of the structures in the eye, including CCT. Its use is well established in the hospital clinic setting, and measurements do not require the use of anaesthetic drops or corneal touch. A drawback of this device is that it is large and heavy, and therefore not portable or as fast to use, unlike the ultrasound pachymeter or the Occuity PM1 device.

Conditions
Glaucoma Eye
Keywords
Cornea, Ocular, Glaucoma
Medical subject headings
Corneal Diseases, Glaucoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05895617
Study groupRoleWhat they receive
Research StudyIs the Occuity pachymeter non inferior in it's measurement of central corneal thickness compared to the ultrasound pachymeter, Lenstar and Pentacam.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To determine whether the Occuity PM1 device is non-inferior in measuring central corneal thickness when compared to ultrasound pachymetry, the Lenstar and the Pentacam.

    The central corneal thickness measurements taken by the three devices: Occuity PM1, the ultrasound pachymeter and Lenstar. Demonstrating that the Occuity PM1 Pachymeter is not inferior to the LenStar in terms of equivalency to a 95% confidence level using the Bland Altmen equation/approach.

    Measured: upto 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jun 2023
  2. Study start15 Jan 2023
  3. Primary completion22 Feb 2023
  4. Study completion19 Apr 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05895617
Sponsor's protocol ID
ETH2021-1765
Status last verified
May 2023
First submitted
12 May 2023
Last updated
8 Jun 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: A published paper will be submitted

Questions about this trial

What is this clinical trial studying?

An observational study of Glaucoma Eye, run by Occuity Limited at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To determine whether the Occuity PM1 device is non-inferior in measuring central corneal thickness when compared to ultrasound pachymetry, the Lenstar and the Pentacam. (time frame: upto 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in